Tivicay is an antiretroviral medication used to treat hiv-1 infection in adults. It belongs to the class of integrase inhibitors that block a viral enzyme required for replication. By binding to the hiv integrase protein, Tivicay prevents the virus from inserting its genetic material into host cell dna. This inhibition stops the virus from establishing a persistent infection and reduces the amount of circulating virus. The reduced viral load helps preserve immune function and slows disease progression in patients receiving appropriate therapy. Tivicay is taken orally in combination with other antiretrovirals as part of a prescribed regimen.

Tivicay is an oral medication classified as an integrase inhibitor used in the treatment of hiv infection. Its pharmacological action involves binding to the viral integrase enzyme preventing the incorporation of hiv genetic material into the host cell genome. By blocking this step the virus is unable to replicate its dna, which reduces viral load in the bloodstream. The reduction in viral replication slows disease progression and helps preserve immune function in patients. The drug is metabolized primarily by the liver enzyme cyp3a4 and eliminated through excretion in the bile. Its selective inhibition of the integrase protein targets only the viral enzyme without significantly affecting host enzymes, leading to a favorable side effect profile. This mechanism provides a strong antiviral effect that complements other antiretroviral agents in combination therapy.

The most common side effects include headache and mild nausea. Fatigue often accompanies these reactions. Some individuals report slight dizziness or light sensitivity. These effects are typically short lived and resolve without intervention. Many people notice no noticeable changes at all. The intensity and frequency of symptoms can vary between individuals. Most side effects are mild and do not require medical attention. Monitoring how you feel after each dose helps track patterns.

The most common side effects of vaccination are generally mild and short lived. Pain at the injection site is frequently reported after the shot. Fatigue often follows immunization and may last a day or two. Headache can occur as a systemic reaction. Muscle aches are another typical response. Low grade fever may develop within the first 24 hours. Nausea is occasionally observed after vaccination. Mild swelling of lymph nodes near the injection area has been noted in some individuals.